Literature DB >> 12942146

Magnetic seizure therapy improves mood in refractory major depression.

Markus Kosel1, Caroline Frick, Sarah H Lisanby, Hans-Ulrich Fisch, Thomas E Schlaepfer.   

Abstract

This report describes the successful treatment of a patient suffering from an episode of drug-resistant major depression using magnetic seizure therapy (MST). The patient suffered from recurrent major depression since adolescence. MST is a novel brain stimulation method using transcranial magnetic stimulation at convulsive parameters in order to induce therapeutic seizures under general anesthesia in the same setting used for electroconvulsive therapy (ECT). The first use of therapeutic magnetic seizure induction in a psychiatric patient took place at the University Hospital in Bern, Switzerland, in May 2000. Results of a recent randomized, within-subject, double-masked trial comparing ECT and MST in 10 patients indicate that MST appears to have less subjective and objective side effects, is associated with faster recovery of orientation, and is superior to ECT on measures of attention, retrograde amnesia, and category fluency. ECT has an unparalleled and well-documented efficacy in severe depression but is associated with cognitive side effects. MST is currently under study in several centers with respect to its antidepressant efficacy. We report here on the treatment of a patient with refractory major depression (DSM IV-R), who underwent a series of 12 sessions of MST in an inpatient setting. Baseline Hamilton Depression Rating Scale (HRSD-21) of 33 and Beck Depression Inventory (BDI) of 40 decreased to 6 and 11 respectively, 1 week after completion of the MST trial. Measures of cognitive functions support the hypothesis that MST is associated with a less severe profile of cognitive side effects. [(99m)Tc]-HMPAO SPECT studies (baseline and 4 days after the completion of the MST trial) point to a raise of blood flow at baseline in the left fronto-parietal region and the brainstem. Our preliminary data support the prospect of antidepressant efficacy of MST and point to a benign cognitive side-effect profile in a patient suffering from severe treatment-resistant major depression.

Entities:  

Mesh:

Year:  2003        PMID: 12942146     DOI: 10.1038/sj.npp.1300293

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  35 in total

Review 1.  Brain stimulation in psychiatry and its effects on cognition.

Authors:  Kate E Hoy; Paul B Fitzgerald
Journal:  Nat Rev Neurol       Date:  2010-04-06       Impact factor: 42.937

2.  [Brain stimulation methods for resistance to therapy].

Authors:  T E Schläpfer
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

3.  What is the role of brain stimulation therapies in the treatment of depression?

Authors:  Daniel M Blumberger; Benoit H Mulsant; Zafiris J Daskalakis
Journal:  Curr Psychiatry Rep       Date:  2013-07       Impact factor: 5.285

4.  Advances in the Management of Treatment-Resistant Depression.

Authors:  Paul E Holtzheimer
Journal:  Focus (Am Psychiatr Publ)       Date:  2010

Review 5.  Multimodal approaches to define network oscillations in depression.

Authors:  Otis Lkuwamy Smart; Vineet Ravi Tiruvadi; Helen S Mayberg
Journal:  Biol Psychiatry       Date:  2015-01-28       Impact factor: 13.382

6.  A systematic review of the neurocognitive effects of magnetic seizure therapy.

Authors:  Shawn M McClintock; Owais Tirmizi; Matthieu Chansard; Mustafa M Husain
Journal:  Int Rev Psychiatry       Date:  2011-10

7.  Individualized Low-Amplitude Seizure Therapy: Minimizing Current for Electroconvulsive Therapy and Magnetic Seizure Therapy.

Authors:  Angel V Peterchev; Andrew D Krystal; Moacyr A Rosa; Sarah H Lisanby
Journal:  Neuropsychopharmacology       Date:  2015-04-28       Impact factor: 7.853

Review 8.  Novel targets for antidepressant therapies.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

9.  Quick recovery of orientation after magnetic seizure therapy for major depressive disorder.

Authors:  George Kirov; Klaus P Ebmeier; Allan I F Scott; Maria Atkins; Najeeb Khalid; Lucy Carrick; Andrew Stanfield; Ronan E O'Carroll; Mustafa M Husain; Sarah H Lisanby
Journal:  Br J Psychiatry       Date:  2008-08       Impact factor: 9.319

10.  Unaltered neuronal and glial counts in animal models of magnetic seizure therapy and electroconvulsive therapy.

Authors:  A J Dwork; J R Christensen; K B Larsen; J Scalia; M D Underwood; V Arango; B Pakkenberg; S H Lisanby
Journal:  Neuroscience       Date:  2009-09-25       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.